Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Home

Person

Lucie Carrié Tillard

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Page 1 of 1

Spatiotemporally resolved colorectal oncogenesis in mini-colons ex vivo

Matthias Lütolf, Freddy Radtke, Nicolas Antoine Vincent Broguiere, Luis Francisco Lorenzo Martin, Tania Hübscher, Amber Dawn Bowler, Jakob Josef Langer, Lucie Carrié Tillard

Three-dimensional organoid culture technologies have revolutionized cancer research by allowing for more realistic and scalable reproductions of both tumour and microenvironmental structures 1-3 . This has enabled better modelling of low-complexity cancer ...

NATURE PORTFOLIO2024

Thymic epithelial organoids mediate T-cell development

Matthias Lütolf, Tania Hübscher, Jakob Josef Langer, Lucie Carrié Tillard

Although the advent of organoids has opened unprecedented perspectives for basic and translational research, immune system-related organoids remain largely underdeveloped. Here, we established organoids from the thymus, the lymphoid organ responsible for T ...

2024

Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity

Matthias Lütolf, Nicolas Antoine Vincent Broguiere, Jakob Josef Langer, Lucie Carrié Tillard

Existing organoid models fall short of fully capturing the complexity of cancer because they lack sufficient multicellular diversity, tissue-level organization, biological durability and experimental flexibility. Thus, many multifactorial cancer processes, ...

2024

Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids

Damien Saugy, Matthias Lütolf, Nathalie Brandenberg, Nicolas Antoine Vincent Broguiere, Krisztian Homicsko, Sylke Höhnel, François Réal Rivest, Lucie Carrié Tillard, Devanjali Dutta

Immunotherapy has emerged as a new standard of care for certain cancer patients with specific cellular and molecular makeups. However, there is still an unmet need for ex vivo models able to readily assess the effectiveness of immunotherapeutic treatments ...

2024